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808Objective: Causes of profound thrombocytopenia (platelet count<60 K) developing days after cardiac surgery
include heparin platelet factor 4 antibodies, thrombotic thrombocytopenic purpura–like antibodies, and
endotoxin generated by pulmonary infections. Modulation of immune-mediated profound thrombocytopenia
with intravenous immunoglobulin could be efficacious for any of these conditions.
Methods: From 2002 to 2010, profound thrombocytopenia developed in 20 consecutive patients within days
after cardiac surgery; 19 patients underwent valve or aortic operations, and 1 patient underwent coronary bypass.
Risk profiles were high preoperatively: Patients’ mean age was 73 years, 50% underwent nonelective
procedures, 100% had comorbidities, and 25% underwent reoperations. When decreasing platelet counts
approached 60 K, intravenous immunoglobulin was started at 1.5 g/kg intravenously over 5 days. Anticoagula-
tion and platelet transfusions were avoided. In 1 patient, profound thrombocytopenia failed to reverse promptly,
and daily plasmapheresis was introduced. Platelet counts before and after interventions were assessed with
linear regression analyses over time, including a spline function and statistical knot coincident with starting
intravenous immunoglobulin.
Results: In 19 of 20 patients, profound thrombocytopenia stabilized and rebounded within 2 to 4 days after
initiating intravenous immunoglobulin. In the remaining slow-responding patient, addition of plasmapheresis
was associated with rapid recovery. In every patient, coincident multiorgan failure reversed, and 19 of 20 patients
recovered uneventfully and survived hospitalization with no limb ischemia or tissue loss. No complications of
intravenous immunoglobulin therapy or plasmapheresis were observed.
Conclusions:Althoughmechanisms of profound thrombocytopenia after cardiac surgery are poorly understood,
they likely relate to inappropriate autoimmune moieties causing peripheral platelet aggregation and
multiorgan failure. A protocol involving immunomodulation with intravenous immunoglobulin supplemented
by plasmapheresis appeared safe and efficacious. Direct immunologic interventions for profound thrombocyto-
penia could improve postoperative outcomes. (J Thorac Cardiovasc Surg 2014;147:808-15)Profound thrombocytopenia (pT) occurring early postoper-
atively is observed in approximately 1% to 3% of patients
after adult cardiac surgery.1 The disorder can be associated
with diffuse intravascular platelet deposition, strokes,
multiorgan failure, venous thrombi, pulmonary embolism,
limb loss, and death.2 Although this syndrome is commonly
called heparin-induced thrombocytopenia (HIT) in current
practice, it is likely that true heparin-associated platelet
factor 4 (PF4) antibodies are etiologic in only a minority
of patients.1 Other likely causes for postoperative platelet
aggregation include thrombotic thrombocytopenic purpuranderbilt University, Nashville, Tenn.
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The Journal of Thoracic and Cardiovascular Surg(TTP)-like antibodies,3 infectious superantigens,4,5 and
gram-negative endotoxin.6,7 Whatever the cause, most
agree that surgical pT is mediated by immune activation/
dysfunction producing inappropriate autoantibodies and
peripheral platelet aggregation. The current therapeutic
standard probably is anticoagulation with direct thrombin
inhibitors,8 although plasmapheresis for removal of autoan-
tibodies recently has shown promise.9
Many types of immune-mediated thrombocytopenia exist
in general medical practice.6 In recent years, another
direct immune intervention, immune modulation using
intravenous immunoglobulin (IVIG), has become a primary
therapy for many of these disorders.10 IVIG contains active
normal human antibodies from more than 10,000 donors
and is highly effective in modulating immune dysfunction
and ‘‘normalizing’’ pathologic immunologic moieties. In
fact, treatment of ‘‘acute immune-mediated thrombocyto-
penia’’ currently is an on-label indication for IVIG.11
Because postoperative pT seems to be primarily immune
mediated, IVIG also could be useful in the postsurgical
setting. This article reports the results of treating pT
with immune modulation using IVIG. Many of these con-
cepts have been published,12 and the purpose of thisery c February 2014
Abbreviations and Acronyms
HIT ¼ heparin-induced thrombocytopenia
Ig ¼ immunoglobulin
IVIG ¼ intravenous immunoglobulin
PF4 ¼ platelet factor 4
pT ¼ profound thrombocytopenia
TTP ¼ thrombotic thrombocytopenic purpura
Rankin and Stratton Perioperative Managementcommunication is to present specific pT data and associated
discussion.P
MMATERIALS AND METHODS
Ethical Considerations
This clinical effort to use IVIG for the purpose of treating pT after adult
cardiac surgery was initiated within a standard cardiac surgical practice in
the setting of a worsening high-risk problem with less than satisfactory
solutions. One could reason that immune modulation for pT was a Food
and Drug Administration on-label indication for IVIG,11 and the concept
was based on existing literature support in similar clinical situations.13-16
Before IVIG was started, possible therapeutic benefits and risks were
discussed with the patients and families, and all agreed to proceed. The
chart review and de-identified data analysis were performed at a later
date under a waiver of informed consent by the Western Institutional
Review Board.
Population
Twenty consecutive patients experiencing pTafter adult cardiac surgery
from 2002 to the middle of 2010 were assessed. The first 14 patients were
part of a previous report on general immune dysfunction from 2002 to the
end of 2009,12 and the final 6 patients were from the subsequent half-year.
Nineteen patients underwent valve or aortic operations, and 1 patient
underwent coronary bypass. Detailed characteristics of the overall immune
dysfunction population have been described,12 and for the patients
experiencing pT in this analysis, specific data are provided in Table 1.
Risk profiles were high: Patients’ average age was 73.0  15.6 years
(mean  standard deviation), 50% underwent nonelective procedures,
100% had comorbidities, 25% underwent reoperations, and more than
half were female. Criteria for diagnosis of pT included a dramatically
decreasing platelet count days after adult cardiac surgery, averaging a
20 K decrease the day before starting IVIG (Figure 1), with no other cause
evident, and with the platelet count approaching 60 K. Most patients had
pulmonary infiltrates associated with pulmonary dysfunction, leukocytosis,
and some degree of multiorgan failure at the time of pT development, and
the few who did not eventually developed pulmonary infiltrates within
days. Postoperative immunoglobulin (Ig)G levels were low in most
(Table 1),12 but were only available later in the series. Heparin PF4
antibody tests were not available early in the series, but when obtained
in later patients, all results were negative.
General Management Protocol
Most patients with pT had evidence of pulmonary infection
with worsening pulmonary infiltrates, signs of sepsis, leukocytosis,
deterioration of pulmonary mechanics, and impairment of pulmonary gas
exchange.12 Multiple-drug intravenous antibiotics (consisting of combina-
tions of piperacillin/tazobactam, cefepime, tobramycin, and meropenem
[vancomycin was used only for specific indications]) were started in all
patients, according to the University of Kentucky antibiotic protocol for
management of hospital-acquired pneumonia.17,18 Platelet transfusions
and anticoagulation with thrombin inhibitors were avoided. All patientsThe Journal of Thoracic and Cawere maintained under full intensive care unit care and had
documentation of good cardiac status with a Swan–Ganz catheter and a
transthoracic echocardiogram at the outset. Pulmonary cultures were
obtained in all patients, including bronchial washings or protected brush
cultures in patients undergoing therapeutic fiberoptic bronchoscopy.
Significant renal dysfunction also developed in 45% of patients,
manifested by oliguria or aneuria with increasing creatinine, despite
intravenous dopamine and diuretic support.12
Intravenous Immunoglobulin Therapy
When the rapidly decreasing platelet count approached 60 K (Figure 1)
and after family agreement, IVIG therapy (Carimune; ZLB Behring Inc,
King of Prussia, Pa) was begun at a dose of 18 or 24 g/d (depending on
the size of the patient, 0.3 g/kg/d) intravenously for 5 days to a total
dose of 1.5 g/kg. In the subsequent spline function analysis, the first day
of IVIG infusion was considered IVIG day 0 for placement of a statistical
knot. More detailed clinical management principles have been outlined by
Rankin and colleagues,12 including the importance of early enteral
nutritional support. However, with IVIG therapy, most patients rapidly
regained their appetites and promptly resumed good oral nutrition.
Analysis Protocol
In all patients, platelet counts were obtained almost daily as part of
routine postoperative care. At a later time, retrospective chart review was
performed, and platelet values were documented for 3 days before
(day 3) beginning IVIG therapy (on day 0) and for 5 days afterward
(day þ5). For a variety of reasons in the clinical setting, 18 of the total
180 platelet count data points (9 data points 3 20 patients) were missing,
and thesewere interpolated by using the arithmetic average of adjacent data
points. In the 20 patients, full IVIG therapy was initiated between the sec-
ond and fifth postoperative days. When IVIG was started on postoperative
day 2, the preoperative platelet count was used as the day3 data point. By
using each patient as his or her own control, the therapeutic effect of IVIG
was assessed with linear regression analysis of platelet counts over time
using a spline function and a statistical knot at day 0, coincident with
beginning IVIG.RESULTS
Most patients had signs of pulmonary infection coinci-
dent with pT. Three patients presented initially with isolated
pT, but pulmonary infiltrates eventually developed. Thus,
postoperative nosocomial infection was the probable
cause in most patients, if not all. No patients had other
complications or evidence of alternative sources of
infection, and no other patients during this period had pT
treated differently or any evidence of limb ischemia. At
the time of IVIG initiation, most patients’ conditions were
deteriorating, with rapidly decreasing platelet counts
(Figure 1), worsening ventilator status, and developing
multiorgan failure.12 In the linear regression analysis over
the 3 days before IVIG, the platelet counts were decreasing
rapidly, and when the decision for IVIG was made (day 0),
general morbidity often was high. Postoperative IgG levels
were usually low in this population (Table 1), although
quantitative IgG levels were available only in later years.
After beginning IVIG on day 0, improvement in clinical
course and reversal of thrombocytopenia were observed
uniformly over the subsequent 5 days. In the spline function
analysis, and using each patient as his or her own control,rdiovascular Surgery c Volume 147, Number 2 809
TABLE 1. Patient characteristics
Patient
no.
Age,
y Sex
No. of
comorbidities Reoperation
Cause of
disease
NYHA
angina
class
NYHA
class for
congestive
heart
failure
Preoperative
albumin
level
Nonelective
presentation Procedure
Pump
time (h)
Postoperative
IgG level
1 62 M 4 N Ischemic mitral
disease
4 1 3.4 Y AM-VR, C34 4.08 —
2 69 M 2 N Mitral prolapse 1 4 2 Y MT-VR 3.35 —
3 78 M 4 N Mitral prolapse 1 4 3.4 Y M-VR, C32 2.93 —
4 69 F 1 Y Mitral prolapse 1 3 3.8 N M-VR, Abl 1.90 —
5 81 F 1 N Calcific 1 4 2.8 Y A-VR, C31 1.97 —
6 75 M 3 N CAD 3 1 4 Y C34 2.02 —
7 57 F 1 N Rheumatic valve
disease
1 3 3.8 N M-VR 3.03 —
8 49 M 2 Y Marfan syndrome
with dissection
1 1 3.4 N Redo 3 5 TAA 6.50 481
9 69 M 1 N Calcific 1 3 3.5 N A-VR, C31,
SMy
2.63 359
10 67 F 2 N PAD 1 4 3.4 N MT-VR, C31 4.10 525
11 77 M 2 N Calcific 1 4 3.2 Y AM-VR, C32,
AAA, Abl
4.55 368
12 80 F 2 N Calcific 1 4 3.7 N A-VR, root
enlarge
3.33 537
13 39 F 3 Y Adult congenital
heart disease
1 4 4.1 N M-VR, Abl 4.43 704
14 57 F 1 Y HOCM 1 3 3.8 N M-VR, SMy,
C31
2.98 583
15 62 F 2 N Rheumatic valve
disease
1 3 3.7 N M-VR, Abl 4.35 833
16 80 F 2 N Mitral prolapse 1 3 3 N M-VR 3.15 431
17 65 M 4 N Calcific 3 3 3.7 Y AM-VR 4.43 789
18 73 F 1 N Mitral prolapse 1 4 3.7 Y M-VR, Abl 3.10 457
19 84 M 2 Y Rheumatic valve
disease
1 3 3.5 Y MT-VR 3.30 741
20 84 F 2 N Calcific 1 4 3.6 Y A-VR, C33 3.58 605
Mean 73.0 55% 3.0 25% — 95% NYHA 3.5 50% 95% complex 3.83 543.0
SD 15.6 F 1.4 Y — Class 3 or 4 0.1 Y Valve/AA 0.35 87.7
A, Aortic; AA, aortic aneurysm; AAA, ascending aortic replacement; Abl, atrial ablation; AM, aortic-mitral; C, coronary bypass; CAD, coronary artery disease;
HOCM, hypertrophic obstructive cardiomyopathy; Ig, immunoglobulin;M, mitral;MT, mitral tricuspid;NYHA, NewYork Heart Association; PAD, pure mitral annular dilatation;
SD, standard deviation; SMy, septal myectomy; TAA, thoracoabdominal aneurysm; VR, valve repair or replacement.
Perioperative Management Rankin and Stratton
P
MIVIG administration was associated with significant
improvement in thrombocytopenia (P<.001), as evidenced
by an increase in platelet count toward normal over the
course of immune modulation (Figure 1). No limb ischemia
was observed in any patient. Despite serious baseline
profiles at day 0, 19 of 20 patients (95%) recovered
uneventfully to hospital discharge. No significant complica-
tions of IVIG therapy occurred. Several patients experi-
enced fever during drug infusion, and the administration
rate was slowed.19
In 1 patient with pT who demonstrated more prominent
TTP-like features (schistocytes, hemolysis, and a negative
heparin PF4 antibody test result), plasmapheresis also was
used over 3 days, with a prompt clinical response. This
patient received extra doses of Ig to compensate for losses
due to plasma exchange. Pulmonary cultures were positive
in less than one third of patients, usually with antibiotic-
resistant gram-negative organisms.12 The 1 patient who
died had an initial good response, but then progressive
sepsis developed and the patient died. Although recovery810 The Journal of Thoracic and Cardiovascular Surgof serum creatinine was prolonged in several patients with
acute renal failure, all surviving patients at some point
recovered renal function to preoperative levels.12 One pa-
tient (#15) did not receive the full 5-day course of IVIG.
When his platelet count rebounded after 2 days of therapy,
the drug was discontinued as a cost-savings effort. Howev-
er, this approach then was attempted in the next 2 patients,
and after they relapsed, IVIG was restarted and the full dose
was completed successfully. By that time, an excellent
meta-analysis had become available indicating that mortal-
ity improvement was better with full-dose and duration
IVIG therapy,20 and limited doses were not attempted again.
DISCUSSION
In 1946, investigators at Harvard Medical School
successfully fractionated human serum into protein and
lipoprotein fractions using 8% ethyl alcohol.21 Then, with
lowering pH, gamma globulin could be extracted but caused
severe reactions when administered intravenously. In 1962,
enzymatic treatment of the purified Ig improved toleranceery c February 2014
FIGURE 1. Mean  standard deviation of platelet counts for 3 days
before (3) to 5 days after (þ5) beginning IVIG therapy in 20 post-
operative patients experiencing pT. IVIG therapy was begun on day zero.
Time course of the therapeutic response was assessed using a linear
regression and spline function, with a statistical knot at day 0, coincident
with starting IVIG. IVIG was associated with a consistent reversal of
developing pT and a highly significant treatment effect, using each patient
as his or her own control (P<.001). See text for details. IVIG, Intravenous
immunoglobulin.
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Switzerland, biochemical techniques were perfected to pro-
duce fully active Ig antibodies for intravenous administra-
tion, labeled IVIG at that time.21 The preparation contains
pooled antibodies from 10 to 60 K plasma donations and
manifests several million types of natural antibodies with
a wide variety of functions. As a blood product, IVIG is ster-
ilized by viral inactivation methods and nanofiltration, and
with proper production techniques, IVIG has never caused a
documented blood-borne infection after millions of doses.
Soon after development, the immunology group in Bern
used IVIG to treat pT in several children with immune-
mediated thrombocytopenia and documented successful re-
sults. Subsequent randomized trials confirmed the safety
and efficacy of IVIG for treatment of immune-mediated
thrombocytopenia, and IVIG has become an on-label first-
line therapy for this disorder. IVIG use has increased from
300 kg per year in 1980 to 100 tons per year in 2010.
More than 34,000 articles are listed in PubMed on IVIG
and its immunomodulatory effects.21
Sowhy has IVIG not been recognized as a valid treatment
for postcardiac surgical pT? One reason is that we really do
not understand the mechanisms of pT in the postoperative
patient. Although heparin PF4 antibodies have been
involved to some extent, it is unlikely that heparin
antibodies are common etiologic factors.1 Because heparin
antibodies develop in up to 40% of cardiac surgical
patients, their presence is not specific enough in any given
patient to fully implicate them. Moreover, most studies
have not found a high incidence of PF4 antibody positivity,The Journal of Thoracic and Caprompting consideration of other immune mechanisms.
Some have proposed TTP-like antibodies, but evaluations
of ADAMTS-13 moieties have been negative.3 Specific
antibody surveys in surgical patients with pT could be
revealing, and detailed immunologic research in the
surgical setting is clearly needed. Infectious superantigens
or gram-negative endotoxins are capable of inducing
platelet aggregation and peripheral platelet deposition,
similar to Escherichia coli Shiga toxin.7 Because all of
our patients had signs of postoperative infection, we favor
an infectious cause, most likely nosocomial pneumonia
with predominantly hospital acquired gram-negative
organisms. Whatever the pathophysiology, the uniform
temporal response to immune modulation in our series
would suggest immune-mediated causes. In fact, the
immediate cessation in platelet count decline and the 1- to
3-day time lag to increasing platelets are suggestive of a
time-dependent immune process. Although a more com-
plete discussion has been published,22,23 it is clear that
immune function represents a complex interrelated system
and that IVIG is effective in suppressing inappropriate
inflammatory responses and in restoring immunologic
homeostasis, probably by multiple mechanisms.
Previous treatment modalities for pT left much to be
desired. Although results have varied, anticoagulation
with thrombin inhibitors have been associated with a
residual incidence of limb loss, multiorgan failure, and
death. Bleeding complications in early postoperative
patients also have been problematic in some experiences.
Plasmapheresis recently has been highly efficacious and
probably removes offending autoantibodies in a rapid
fashion. This intervention was effective in 1 of the patients
in this series, and we have used it successfully twice
subsequently. At this point, it is reasonable to propose
inducing immune ‘‘normalization’’ with plasmapheresis
(especially in patients with dialysis catheters in place or if
the response to IVIG is slow) and then continuing
immunomodulation with IVIG. Although some patients
with rapidly decreasing platelet counts may not have
immune-mediated pT (patient 15 was atypical with a
normal IgG level and responded to 2 doses), we believe
the protocol should be applied consistently to prevent the
devastating complication of limb thrombosis (especially
because IVIG complication rates are negligible). At some
point, proper diagnostic tests may become available for
immune-mediated pT, but until then, routine application
seems justified.
IVIG has been implicated in causing renal dysfunction
when given in high doses. However, at the dose schedule
used in this series, complications have not been observed,
and all patients with developing renal failure eventually
recovered baseline renal function.12 Never before have we
had a method of directly treating postoperative renal failure,
which in our experience almost always suggests developingrdiovascular Surgery c Volume 147, Number 2 811
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Minfection. Other complications of IVIG were not observed,
and the 5% of patients experiencing febrile responses were
easily managed by slowing infusion. IVIG obviously is
an expensive drug, and a full course costs $4 to $8 K,
depending on the hospital’s contracting mechanism.
However, IVIG is likely cost-effective, considering that
patients with thrombin inhibitor therapy had a mean
hospitalization of 38 days in a recent series,1 whereas
because of rapid clinical recovery, half of patients receiving
IVIG were discharged after the fifth and last dose.12
In the final analysis, the best treatment for this disorder
would be prevention. A good candidate for primary cause
is nosocomial pneumonia, which is increasing nationally.24
Multiple interventions exist to reduce postoperative
pulmonary infections,25 and better maintenance of
operating room ventilators could be important. The aqueous
environment of an unmaintained volume ventilator is ideal
for gram-negative organisms, and in most major US centers,
the devices are never cleaned. This is in contrast to the
meticulous ventilator maintenance performed at German
heart centers, in which postoperative pneumonia and pT
are uncommon.26 Another recently defined nosocomial
infection source is contaminated intravenous solutions.27
The revelation that cardioplegia solutions produced by the
New England Compounding Center and used by many US
hospitals were contaminated by black mold (Exserohilum
rostratum) changes the meaning of the word ‘‘nosocomial.’’
A major epidemiologic effort needs to be expended in US
hospitals to reduce perioperative infection sources.
Most surgical patients in whom postoperative immune
dysfunction develops are undergoing complex valve
procedures (Table 1).12 They often are elderly and
debilitated, frequently are emergency cases, and have
longer cardiopulmonary bypass times. In a previous study
of the first author’s series,28 various manifestations of
immune dysfunction developed in 18% of valve surgery
cases and were treated with IVIG. Compared with earlier
patients (n ¼ 370) undergoing valve surgery, patients
undergoing valve surgery with the backup of an IVIG
protocol (n ¼ 171) had sicker baseline profiles, probably
because of the later time period. Because immune
dysfunction always has been an important cause of
postoperative morbidity and mortality (perhaps the most
important), effective management with IVIG decreased
overall valve surgery mortality from 7.3% before the
IVIG protocol to 1.2% after IVIG availability. Thus, a
postoperative immune management protocol applied with
highly selective criteria seems effective in reducing overall
operative mortality29 and limiting morbidity associated
with pT.
Study Limitations
IVIG therapy was not randomized, and most drug studies
require randomized trials to ensure absence of treatment812 The Journal of Thoracic and Cardiovascular Surgselection bias or confounding variables. Although this is a
valid consideration, the concept of IVIG efficacy for
immune-mediated pT has been established on multiple
occasions, and the therapeutic response has been so
consistent that the observation seems strong. In addition,
the spline function analysis, using each patient as his or
her own control, is a powerful assessment, suggesting
temporal cause and effect rather than an association as in
a randomized trial.30 Lack of patient randomization remains
a limitation, although at the current level of experience, a
randomized trial may be unethical.
CONCLUSIONS
IVIG administered to patients experiencing pT after
cardiac surgery promptly and effectively reversed deterio-
rating platelet counts without major complications. Immune
augmentation with IVIG offers the exciting possibility of
effectively treating one of the significant problems
encountered in cardiac surgical practice today and
improving postoperative results. Studies of immunomodu-
latory mechanisms seem indicated.
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MDiscussion
Dr Nevin Katz (Baltimore, Md). This is an important report.
This study addresses the important clinical issue of thrombocyto-
penia, which is not unusual in this current era of cardiac surgery in
patients who have undergone complex cardiac surgery or who
have ongoing infection or multiorgan system dysfunction
postoperatively. The results of IVIG in your patients is impressive.
My first question regards the limitation of the study that you
have recognized, and you mentioned that it is a nonrandomized
study. There is no control group.
During the study period, did you encounter patients who
developed postoperative thrombocytopenia of less than 60,000
but did not choose to receive the IVIG. If you did, could you
comment on the courses of their platelet counts, and if present,
the courses of their respiratory, renal, and infectious issues?
Dr Rankin. I am troubled by the limitations of randomized
trials, and I have been involved with many of them over the years.
They are good for some things, and studies that involve drugs
usually require randomized trials for on-label approval. ThereThe Journal of Thoracic and Cahave been many randomized trials using IVIG to modulate im-
mune thrombocytopenia, and they all have been positive. It works.
In regard to nontreated patients, I did not have anyone who
refused IVIG during this period. I was thinking, as you were talk-
ing, back to 1970, and my internship at Alabama (your former
institution). At that time, I saw my first patient whose toes turned
black after mitral valve surgery, associated with thrombocytopenia
and multiorgan failure. So this disorder has been around for a
while, and it has been one of the most frustrating problems that
we encounter.
Then in the 1980s, Chuck Greenberg and Jim Lowe’s first
publication on heparin-associated thrombocytopenia thrombosis
syndrome had 2 of my patients in it from Duke, and we would
see this problem not infrequently in that era and since. So I have
had a lot of experience with this syndrome over the years, and I
have to say that since 2002 and institution of the IVIG protocol,
it has been a relief to have zero patients with major complications
from it. IVIG has been effective in every single patient
experiencing a rapidly decreasing platelet count and immune
dysfunction. Sometimes it takes several days to turn around, and
I have 3 patients now in whom plasmapheresis was used in a
complementary fashion in the first few days of therapy.
I am not sure that, at this point, a randomized trial would be
ethical, given all the previous data with IVIG and immune
thrombocytopenia. Indications are that the surgical variety is just
another form of immune dysfunction like all the medical forms.
The immune moiety, or inappropriate autoantibody, probably is
going to be different. We need to explore that in basic
immunologic research. I think it is clear that this problem is
immune-mediated, and modulation with IVIG seems safe and
extremely effective in the surgical setting.
Dr Katz. My second question has to do with the mechanism,
and I think it is one of the important points of this report is detailing
the various causes that could explain this. Because many people
have thought that if the PF4 antibody test is negative, then it is
not ‘‘HIT.’’ So it is important to look at the mechanism.
Now, the fact that all but 1 patient in your series underwent
valve or aortic surgery raises the question whether the decreased
platelet counts were related to mechanical trauma to the platelets
by passage of blood through the cardiotomy suction system of
the pump oxygenator. I am wondering if you consider trauma
related to heart-lung machines as a factor, and can you relate
that to the immunologic mechanism?
Dr Rankin. It is unclear exactly what is going on there. If we
look at our larger series of immune dysfunction, the factors that
are common to these patients includeworse baseline profiles, older
sicker people, and longer pump runs. Pre-existing immune
disorders, such as rheumatoid arthritis or lupus, also are common.
But it is mostly patients with complex valves, multiple valves in
the elderly population, and so on, who get this syndrome. In a
quick 1-hour pump run or 1.5-hour pump run for a coronary
bypass, it is less common.
I believe it is more related to the duration of cardiopulmonary
bypass and the degree of dysregulation of the immune system. Since
we have been obtaining IgG levels postoperatively, the majority of
these patients have low postoperative IgG levels. Sometimes, it will
be 200 or 300 with a lower limit of 650. It is hard to know cause and
effect, because some infections are known to consume IgG, but lowrdiovascular Surgery c Volume 147, Number 2 813
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1000 after surgery, the patient rarely gets this problem. It is related,
I think, to immune dysregulation contributed to in a major way by
cardiopulmonary bypass. With nosocomial infection sources,
immune depletion predisposes to the development of pulmonary
infection. I believe most of these patients have gram-negative noso-
comial pneumonias as their underlying problem.
I submitted an abstract 15 years ago saying that HITwas a major
factor in postoperative mortality because 25% of the patients who
died had thrombocytopenia syndrome, and I proposed that HIT
then caused pulmonary dysfunction, pulmonary infiltrates, and
multiorgan failure. Now, I am sure it is the other way around,
that it is mostly infection-related. If I go to Germany where they
maintain their operating room ventilators well, postoperative
pneumonia is unusual. It might help US centers if they studied
German infection control protocols.
Dr Katz. That is an interesting observation.
Dr Rankin. I do not have data on that; it is just my personal
impression.
Dr Katz. Yes, but an interesting observation.
Dr Rankin. Yes.
Dr Katz. My final question. In this era of cardiac surgery, it
certainly is not unusual to see platelet counts less than 60,000,
and there are 3 groups of patients, at least in our practice, that
I think I can identify in whom it is common. One group includes
patients who have undergone reoperative surgery and have a
coagulopathy postoperatively often related to perioperative
antiplatelet therapy. The second group includes patients who are
on ventricular assist devices and are undergoing extracorporeal
membrane oxygenation. The third group includes patients who
are being treated for sepsis postoperatively. On the basis of your
study, would you recommend that IVIG be used in these groups
of patients to decrease the need for platelet transfusions and
improve outcomes related to multiorgan system dysfunction?
Dr Rankin. Prophylactically?
Dr Katz. Well, if you see the platelet count go down.
Dr Rankin. Yes.
Dr Katz. To maybe not 60,000, but you are seeing it go down,
let’s say, to less than 100,000, and you have someone on a
ventricular assist device, do you think that it is appropriate to do
that, or would you interpret the platelet count going down because
of the system, the ventricular assist device or the extracorporeal
membrane oxygenation system?
Dr Rankin. I do not have experience with the population with
ventricular assist devices, and all the patients I reported today are
probably in your third category with infection as the cause. IVIG
works there, but I do not have experience with assist devices.
Certainly, there were patients in this series who experienced
bleeding postoperatively and had transfusions, which probably is
one risk factor, as we have discussed, but platelet counts were
all restored to normal before the pT developed.
Dr Harold Burkhart (Rochester, Minn). Did you look into IgG
levels before and after? Did you check that? I may have missed it.
Dr Rankin. Yes. Halfway through this series, around 2006, we
obtained the ability to get IgG levels after surgery. As I said, the
majority have low IgG levels immediately after surgery.
Dr GlennWhitman (Baltimore, Md). I thought I saw that there
were no positive cultures in this population, and yet I also thought I814 The Journal of Thoracic and Cardiovascular Surgheard you are attributing thrombocytopenia in this population to
Gram-negative septicemia. Could you explain the relationship
further?
Second, would you suggest that every patient who has
Gram-negative septicemia with thrombocytopenia be treated
with IVIG whether or not they had cardiac surgery?
Dr Rankin. Regarding your second question, infection-related
thrombocytopenia, from my interpretation of the literature, is an
on-label indication for IVIG at present, for example, Shiga toxin
cases. About your first question, I don’t think I said there were
no positive cultures. I said there were no patients with positive
PF4 antibodies. But our particular hospital has been a little
inconsistent with that test; we still have to send it to a remote
laboratory, so my confidence in the PF4 results is not perfect.
We were actually sending heparin-induced platelet aggregation
studies to Duke for Greenberg’s laboratory for a while, but again,
the majority were not positive. In fact, in most publications, it has
been unusual to have a positive PF4 in this population, usually with
less than one third of patients exhibiting PF4 positivity.
In our published series of immune dysfunction in the Journal in
2011, approximately one third of these patients had positive
pulmonary cultures, usually with Gram-negative rods, usually
multidrug resistant. As you know from the literature, it is difficult
to culture these kinds of organisms, with 30% to 40% positivity
being fairly standard around the world. I believe most of these
problems probably are related to postoperative pulmonary
infection of one sort or another.
Dr Lyle Joyce (Rochester, Minn). So are all patients candidates
or are there some patients who you would not treat?
Dr Rankin.Well, yes. Now, in a way, it is easier. I have stopped
ordering PF4s; up to 40% of patients eventually turn positive after
surgery anyway, so it is not a specific test. If the patient is 2 or 3
days postoperative, the IgG level is low, and the platelet count is
plummeting, I just start the IVIG protocol. It is very important
to complete the entire protocol (1.5 g/kg intravenously over 5
days) and not just a dose or 2. It seems clear to me that most of
the likely causes of pT are immune-mediated in one way or the
other, and they all seem to respond to IVIG in my series.
Dr Joyce. You will not wait for a negative hit, then?
Dr Rankin. Oh, no.
Dr Joyce. You just go ahead and get started?
Dr Rankin.Well, if it is a TTP-like antibody, as several articles
propose, it works there. If it is endotoxin, it works there. If it is a
PF4 antibody, IVIG is a standard therapy. The immune modulatory
effects of IVIG are effective in all those settings, and it has been
100% effective in our population.
Dr Joseph Rubelowsky (Hattiesburg, Miss). This is a fasci-
nating topic because I am dealing with this in exactly the same
population you are talking about with multivalves and patients
who develop renal failure. I round in the morning and say oh
my, the platelet count is low.
Now that I have this in my armamentarium, I never considered
this. But one thing I would be interested in is with my patient who
recently had a low platelet count and vancomycin-resistant
Enterococcus, and it was terrible. But I am always worried,
and like you said, this happens in valve cases. Then I have
transesophageal echocardiograms to show there were no
vegetations or paravalvular leaks.ery c February 2014
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out, are they coming back with paravalvular abscesses or infective
endocarditis, or do you keep them on long-term antibiotics just to
make sure that if they were septic, that we killed that bug and they
are not going to have a problem with that valve?
Dr Rankin. As we have written in our immune dysfunction
articles in the Journal and The Journal of Heart Valve Disease,
proper antibiotic coverage together with augmenting the immune
system are both important.The Journal of Thoracic and CaSo, it pays to obtain good bronchoalveolar cultures and use
good antibiotic protocols. I am sure that secondary endocarditis
can occur. I’ve had that happen in the remote past. But in this
series, once the patients got over the pulmonary infection and their
white blood counts returned to normal, the pT did not recur. I had 1
patient who required a second valve operation 1 week after
receiving IVIG for serious thrombocytopenia, and with the IVIG
on board, the thrombocytopenia did not recur. It looks to be an
effective therapy in the postsurgical setting.rdiovascular Surgery c Volume 147, Number 2 815
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